Treatment-Resistant Depression
You did the thing that’s supposed to help. You got the diagnosis, you started the medication, you gave it the weeks it needed, and you waited for the lift that everyone talks about. Maybe it helped a little. Maybe it didn’t help at all. Maybe you tried a second one, and a third and you’re still here, still carrying the weight, now with the added burden of wondering what’s wrong with you that the thing that’s supposed to work isn’t working.
Nothing is wrong with you. What you’re describing has a name — treatment-resistant depression and it is far more common, far better understood, and far more treatable than most people realize. This article is here to walk you through what it actually means, why it happens, and what comes next.
What “Treatment-Resistant” Actually Means
The clinical definition of treatment-resistant depression (TRD) is an inadequate response to two or more adequate trials of antidepressant medication, meaning the right medication, at an adequate dose, for an adequate duration (typically at least four to six weeks), without sufficient improvement.
The first thing worth understanding is how common this is. Recent estimates place the prevalence of TRD at roughly 30 to 40 percent of people treated for depression with antidepressants. That is not a small subset of unlucky cases, it is something close to a third of everyone who starts down this road. If you are in this group, you are in the majority of a very large group, not the exception.
The second thing worth understanding comes from one of the most important studies ever conducted on depression treatment: the STARD trial (Sequenced Treatment Alternatives to Relieve Depression), funded by the National Institute of Mental Health. STARD followed thousands of patients through up to four sequential treatment steps, each one used when the previous step hadn’t produced remission. The remission rates at each step were 37 percent, 31 percent, 14 percent, and 13 percent. Two things stand out from these numbers. First, the rate drops at each step, finding the right treatment can take more than one or two tries, and that’s the norm, not a red flag. Second, and this is the more important point – the cumulative remission rate across all four steps was nearly 70 percent. Most people who didn’t respond to the first treatment did eventually find one that worked. The process took longer than anyone would want. But it worked.
Before Changing Course: What a Careful Reassessment Looks Like
When a medication doesn’t seem to be working, the instinct is often to jump straight to “what’s next”, a new drug, a higher dose, an add-on. But a careful clinician starts somewhere else: by re-examining the fundamentals, because sometimes what looks like treatment resistance is actually something else.
Is the diagnosis right?
This is the single most important question, and it is asked less often than it should be. Depression that doesn’t respond to standard antidepressants is sometimes not unipolar depression at all, it may be the depressive phase of bipolar disorder, which often responds poorly, or even worsens, on antidepressants used alone without a mood stabiliser. A careful history, including any periods of unusual highs, even brief or long-ago ones can change the entire picture.
Was the dose and duration actually adequate?
“I tried that medication and it didn’t work” sometimes means a full, adequate trial happened. And sometimes it means the dose never reached a therapeutic level, or the medication was stopped after two weeks because of side effects, before it had time to work. Reviewing exactly what was tried, the specific medication, the dose, how long it was taken, and what happened often reveals that what looks like “this class of medication doesn’t work for me” is actually “this specific trial wasn’t adequate.”
Are there other factors complicating the picture?
Several conditions and circumstances can make depression harder to treat and easy to miss: untreated sleep disorders (including sleep apnea), thyroid dysfunction (an underactive thyroid can produce a clinical picture nearly indistinguishable from depression), vitamin deficiencies, chronic pain, substance use (including alcohol, which directly counteracts antidepressant effects), and significant ongoing life stressors that no medication can fully address on its own. A thorough reassessment looks at all of these, not because medication doesn’t matter, but because medication works best when it isn’t fighting an unaddressed second problem.
Adherence without judgment
Missing doses, taking medication inconsistently, or stopping and restarting are extremely common, and they are not moral failings, they are often signs that the side effects were harder to tolerate than anyone acknowledged, or that the reason for taking the medication wasn’t clear, or that life simply got in the way. A good clinician asks about this directly and without judgment, because the answer changes what “treatment resistant” actually means in your case.
What Comes Next — The Evidence-Based Options
Once the fundamentals have been reviewed, several well-supported paths exist for depression that hasn’t responded to initial treatment.
Switching medications
Moving to a different antidepressant, sometimes within the same class, sometimes to a different class entirely (for example, from an SSRI to an SNRI, or to a medication with a different mechanism such as bupropion or mirtazapine), is often the first step. Different medications affect different neurotransmitter systems and combinations of systems, and a medication that didn’t help may simply not have matched your particular biology. This is genuinely a matter of finding the right match, not a hierarchy of “stronger” or “weaker” drugs.
Augmentation — adding a second medication
Rather than switching entirely, augmentation involves adding a second medication to enhance the effect of the first. One of the better-studied augmentation strategies involves adding a low dose of an atypical antipsychotic, such as aripiprazole, to an existing antidepressant, an approach that has shown meaningfully improved remission rates in clinical trials. Other augmentation strategies include adding lithium, thyroid hormone (even in people with normal thyroid function, in some cases), or a second antidepressant with a complementary mechanism. Augmentation is typically considered when a medication has produced a partial response, some improvement, but not enough, rather than no response at all.
Esketamine and ketamine-based treatments
For depression that has not responded to multiple standard treatments, esketamine (a nasal spray, brand name Spravato) is FDA-approved specifically for treatment-resistant depression, used in conjunction with an oral antidepressant and administered under medical supervision. It works through a fundamentally different mechanism than traditional antidepressants targeting the glutamate system rather than serotonin or norepinephrine and for some people produces improvement notably faster than conventional medications, sometimes within days to weeks rather than the typical four-to-eight-week window. Systematic reviews from 2025 have continued to find significant symptom improvement compared to placebo, often becoming apparent by around four weeks of treatment.
Transcranial Magnetic Stimulation (TMS)
TMS is a non-invasive procedure that uses magnetic fields to stimulate specific regions of the brain associated with mood regulation. It is FDA-approved for depression that hasn’t responded to at least one antidepressant trial, involves a series of sessions over several weeks, requires no anesthesia or sedation, and carries a favourable side-effect profile compared to more invasive options. Research continues to support its effectiveness for people who haven’t found relief through medication alone.
What This Means for You
If you’ve tried medication and it hasn’t worked or hasn’t worked enough, here is what is genuinely true: that information is valuable, not discouraging. Every medication tried, every dose, every response (or lack of one) tells your prescriber something real about how your particular biology responds to particular interventions. None of it was wasted. All of it narrows the search.
The STAR*D numbers are worth holding onto: nearly 70 percent of people who didn’t respond to the first treatment eventually found one that worked, across up to four sequential steps. The process can be slow and frustrating in a way that’s genuinely hard when you’re the one living through it. But “slow” is not the same as “hopeless,” and the data backs that up.
What matters most at this stage is having a prescriber who takes the time for the reassessment described above, who doesn’t simply repeat the same approach with a different label, but who actually looks at the whole picture: the diagnosis, the history of what’s been tried, the other factors that might be at play, and the full range of next steps, including the newer options that didn’t exist a decade ago.
A Word on Time and Why It’s Not Wasted Time
One of the hardest parts of this process is the sheer duration of it. Each medication trial takes weeks to evaluate properly, typically four to eight weeks at an adequate dose before a provider can say with confidence whether it’s working. If a switch or an augmentation is needed, that’s another four-to-eight-week window. For someone in the middle of a depressive episode, the idea of “let’s see how you feel in six weeks” can feel unbearable, especially after it’s already happened more than once.
It helps to reframe what’s happening during those weeks. This isn’t a wait in the sense of nothing happening, it’s an active clinical trial, in the truest sense of the word, where data is being gathered about how your specific biology responds to a specific intervention. A provider who is genuinely engaged during this period isn’t just waiting alongside you; they’re tracking your response closely, watching for early signals, adjusting for side effects, and using everything that happens, including the parts that don’t work, to narrow down what will. The six weeks of an unsuccessful trial are not six wasted weeks. They’re six weeks of information that the next step gets to use.
This is also where having consistent access to your provider matters most. The gap between “this isn’t working” and “let’s try something different” shouldn’t be another three-month wait for the next available appointment. Same-week access and ongoing telehealth check-ins mean that when a treatment plan needs adjusting, the adjustment can happen close to when it’s needed, not months later, after an already difficult stretch has gone on even longer than it needed to.
Frequently Asked Questions
How many antidepressants do people typically need to try before finding one that works?
There’s no fixed number, but the STAR*D trial found that about 37 percent of people achieved remission on the first medication, and the cumulative rate climbed to nearly 70 percent by the fourth treatment step. Many people find an effective treatment on the first or second try; others need more steps. Both are within the normal range of how depression treatment works.
Does treatment-resistant depression mean I’ll never feel better?
No. “Treatment-resistant” describes a response to specific treatments tried so far, it is not a permanent diagnosis or a ceiling on what’s possible. With a thorough reassessment and access to the fuller range of options (switching, augmentation, esketamine, TMS, and others), the majority of people with TRD do find meaningful improvement.
Is it normal to feel discouraged after multiple treatments haven’t worked?
Completely. Depression itself can produce hopelessness, and repeated treatment attempts that haven’t worked can compound that feeling in ways that are hard to separate from the underlying condition. This is exactly the kind of moment where having a provider who is actively reassessing, rather than one you feel you’re navigating alone, makes a meaningful difference, both clinically and emotionally.
If antidepressants haven’t worked the way you hoped, that’s information worth bringing to a fresh, thorough evaluation, not a reason to give up. Eva Kirara, MSN, PMHNP-BC offers 100% telehealth psychiatric care with same-week appointments and no referral needed, for adults in Texas, New York, Arizona, and Vermont. Visit lifewisementalhealth.com or call 737-325-1490.
If you’re in crisis or thinking about harming yourself, call or text 988 (Suicide and Crisis Lifeline), available 24/7. If you’re in immediate danger, call 911.